Claims for Patent: 10,533,032

Summary for Patent: 10,533,032

Title:	Crystalline form of benzylbenzene SGLT2 inhibitor
Abstract:	Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
Inventor(s):	Mengzhuang Cai, Qian Liu, Ge Xu, Binhua Lv, Brian Seed, Jacques Roberge
Assignee:	Theracosbio LLC
Application Number:	US15/804,074
Patent Claims:	1. A method of treating a disease or condition affected by inhibiting SGLT2, said method comprising administering to a subject in need thereof a therapeutically effective amount of a crystalline form of (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, having the formula wherein said crystalline form is characterized by an X-ray powder diffraction (XRPD) pattern that comprises peaks at 11.2, 12.9, 15.5, 17.8, 19.1, 20.0 and 20.7 degrees 2θ, ±0.1 degrees 2θ, wherein said XRPD is made using CuKα1 radiation; or said crystalline form is characterized by a Raman spectra that comprises peaks at about 353, 688, and 825 cm−1. 2. The method of claim 1, wherein said crystalline form of (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol is characterized by an XRPD that further comprises peaks at 5.4, 11.3, 11.9, 16.3, 20.6, 21.2, 22.8, 23.0, 23.4, 23.6, 23.9, 24.7, 25.4, 25.8, 27.8 and 28.2 degrees 2θ, ±0.1 degrees 2θ, wherein said XRPD is made using CuKα1 radiation. 3. The method of claim 1, wherein said crystalline form of (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol is characterized by a Raman spectra that further comprises peaks at about 1178, 1205, 1212, 1608, 2945, 3010 and 3063 cm−1. 4. The method of claim 1, wherein said crystalline form of (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol is characterized by a Raman spectra that comprises peaks at about 144, 189, 216, 226, 284, 315, 353, 387, 419, 432, 449, 503, 530, 565, 594, 638, 688, 716, 728, 755, 790, 825, 850, 884, 901, 919, 934, 974, 984, 1014, 1030, 1052, 1070, 1120, 1134, 1178, 1205, 1212, 1229, 1302, 1323, 1343, 1380, 1422, 1438, 1457, 1572, 1585, 1608, 2844, 2919, 2945, 2963, 2997, 3010, 3028, 3051, 3063, 3085, and 3095 cm−1. 5. The method of claim 1, wherein said crystalline form of (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol is characterized by a differential scanning calorimetry (DSC) endotherm at about 136° C. 6. The method of claim 1, wherein said crystalline form of (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol is characterized by the following unit cell data: Family and Space Group Monoclinic P21 (#4) Z′/Z 1/2 a (Å) 7.960 b (Å) 8.860 c (Å) 16.560 α (deg) 90 β (deg) 95.71 γ (deg) 90 Volume (Å3/cell) 1162.1 V/Z (Å3/asym. unit) 581.1 Assumed Composition C24H29O7Cl Density (g/cm3) 1.329 Weight Fraction Solvent (%) N/A. 7. The method of claim 1, wherein said disease or condition is selected from the group consisting of type 1 diabetes mellitus, type 2 diabetes mellitus, hyperglycemia, diabetic complications, insulin resistance, metabolic syndrome, hyperinsulinemia, hypertension, hyperuricemia, obesity, edema, dyslipidemia, chronic heart failure, atherosclerosis, and cancer. 8. The method of claim 1, wherein said disease or condition is type 1 diabetes mellitus. 9. The method of claim 1, wherein said disease or condition is type 2 diabetes mellitus. 10. The method of claim 1, wherein said disease or condition is diabetic complications and said diabetic complications are selected from the group consisting of retinopathy, nephropathy, renal disease, neuropathy, ulcers, micro- and macroangiopathies, and diabetic foot disease. 11. The method of claim 1, wherein said subject is a human. 12. The method of claim 9, wherein said subject is a human. 13. The method of claim 1, further comprising administering an additional therapeutic agent. 14. The method of claim 13, wherein said additional therapeutic agent is selected form the group consisting of an antidiabetic agent, a lipid-lowering agent, an agent for treating diabetic complications, an anti-obesity agent, and anti-hypertensive agent, an antihyperuicemic agent, and an agent for treating chronic heart failure. 15. The method of claim 13, wherein said additional therapeutic agent is an antidiabetic agent. 16. The method of claim 15, wherein and said antidiabetic agent is selected from the group consisting of insulin and insulin mimetics, acetohexamide, carbutamide, chlorpropamide, glibenclamide, glibornuride, gliclazide, glimepiride, glipizide, gliquidone, glisoxepide, glyburide, glyclopyramide, tolazamide, tolcyclamide, tolbutamide, JTT-608, glybuzole, metformin, buformin, phenformin, repaglinide, nateglinide, mitiglinide, rosiglitazone, pioglitazone, isaglitazone, netoglitazone, rivoglitazone, balaglitazone, darglitazone, CLX-0921, farglitazar, metaglidasen, MBX-2044, GI 262570, GW1929, GW7845, muraglitazar, naveglitazar, tesaglitazar, peliglitazar, JTT-501, GW-409544, GW-501516, PLX204, GlaxoSmithKline 625019, GlaxoSmithKline 677954, ALRT-268, AGN-4204, MX-6054, AGN-194204, LG-100754, bexarotene, acarbose, miglitol, L-783281, UCL-1397, sitagliptin, vildagliptin, denagliptin, saxagliptin, alogliptin, dutogliptin, NVP-DPP728, P93/01, P32/98, FE 99901, TS-021, TSL-225, GRC8200, KR61639, PNU-177496, CP-368296, CS-917, MB05032, AZD-7545, FR-225659, carbenoxolone, INCB13739, BAY-27-9955, NN-2501, NNC-92-1687, exenatide, liraglutide, LY-315902, and GlaxoSmithKline 716155. 17. The method of claim 13, wherein said additional therapeutic agent is an agent for treating diabetic complications. 18. The method of claim 17, wherein said an agent for treating diabetic complications is selected from the group consisting of epalrestat, imirestat, tolrestat, minalrestat, ponalrestat, zopolrestat, fidarestat, ascorbyl gamolenate, ADN-138, BAL-ARI8, ZD-5522, GP-1447, IDD598, risarestat, zenarestat, methosorbinil, AL-1567, M-16209, AD-5467, AS-3201, NZ314, SG-210, JTT-811, lindolrestat, sorbinil, pyridoxamine, OPB-9195, ALT-946, ALT-711, pimagedine, ALT-711, sulodexide, 5-hydroxy-1-methylhydantoin, insulin-like growth factor-I, platelet-derived growth factor, epidermal growth factor, nerve growth factor, uridine, uboxistaurin, midostaurin, mexiletine, oxcarbazepine, dexlipotam, GPI-5232, GPI-5693, carnitine, levacecamine, and levocarnitine. 19. The method of claim 13, wherein said additional therapeutic agent is an antihypertensive agent. 20. The method of claim 19, wherein said an agent for treating diabetic complications is selected from the group consisting of bimoclomol, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, thiorphan, omapatrilat, MDL-100240, fasidotril, sampatrilat, GW-660511, mixanpril, SA-7060, SLV-306, ecadotril, candesartan cilexetil, eprosartan, irbesartan, losartan, olmesartan medoxomil, telmisartan, valsartan, tasosartan, enoltasosartan, CGS 35066, CGS 26303, CGS31447, SM-19712, racleer, sitaxsentan, ambrisentan, TBC-3214, BMS-182874, BQ-610, TA-0201, PD180988, BMS-193884, darusentan, TBC-3711, bosentan, tezosentan, J-104132, YM-598, 50139, SB-234551, ATZ-1993, RO-61-1790, ABT-546, enlasentan, BMS207940, hydrochlorothiazide, bendroflumethiazide, trichlormethiazide, indapamide, metolazone, furosemide, bumetanide, torsemide, chlorthalidone, metolazone, cyclopenthiazide, hydroflumethiazide, tripamide, mefruside, benzylhydrochlorothiazide, penflutizide, methyclothiazide, azosemide, etacrynic acid, torasemide, piretanide, meticrane, potassium canrenoate, spironolactone, triamterene, aminophylline, cicletanine, LLU-alpha, isosorbide, D-mannitol, D-sorbitol, fructose, glycerin, acetazolamide, methazolamide, OPC-31260, lixivaptan, conivaptan, amlodipine, bepridil, diltiazem, felodipine, isradipine, nicardipen, nimodipine, verapamil, S-verapamil, aranidipine, efonidipine, barnidipine, benidipine, manidipine, cilnidipine, nisoldipine, nitrendipine, nifedipine, nilvadipine, felodipine, pranidipine, lercanidipine, isradipine, elgodipine, azelnidipine, lacidipine, vatanidipine, lemildipine, diltiazem, clentiazem, fasudil, bepridil, gallopamil, indapamide, todralazine, hydralazine, cadralazine, budralazine, acebutolol, bisoprolol, esmolol, propanolol, atenolol, labetalol, carvedilol, metoprolol, amosulalol, terazosin, bunazosin, prazosin, doxazosin, propranolol, atenolol, metoprolol, carvedilol, nipradilol, celiprolol, nebivolol, betaxolol, pindolol, tertatolol, bevantolol, timolol, carteolol, bisoprolol, bopindolol, nipradilol, penbutolol, acebutolol, tilisolol, nadolol, urapidil, indoramin, clonidine, methyldopa, CHF-1035, guanabenz acetate, guanfacine, moxonidine, lofexidine, talipexole, reserpine, warfarin, dicumarol, phenprocoumon, acenocoumarol, anisindione, phenindione, ximelagatran, aspirin, clopidogrel, ticlopidine, dipyridamole, cilostazol, ethyl icosapentate, sarpogrelate, dilazep, trapidil, and beraprost.